Evaluation of Miricorilant on Liver Fat in Patients With MASLD

Prior treatment

• Significant alcohol consumption exceeding 20 g/day for women or 30 g/day for men within 1 year prior to screening.
• Positive urine drug screen for amphetamines, cocaine, opiates, or cannabinoids.
• History of myocardial infarction, unstable angina, or stroke within 3 months prior to screening.
• Current use of medications prohibited due to potential drug-drug interactions with study treatment.

Other illness

• Other chronic liver diseases such as hepatitis B or C, autoimmune hepatitis, primary biliary cholangitis, or Wilson's disease.
• Uncontrolled hypertension (systolic \> 160 mm Hg or diastolic \> 100 mm Hg).

Other

• Participation in another clinical trial for MASH or weight loss (e.g., GLP-1 receptor agonists) within the last 3 months.
• Participation in any other clinical trial within the last 3 months or 5 half-lives of the treatment, whichever is longer.
• Women who are pregnant, planning to become pregnant, or lactating.
• BMI \< 18 kg/m² or \> 45 kg/m².
• Known or suspected cirrhosis or signs of hepatic decompensation.
• Contraindications to magnetic resonance imaging (MRI).
  • Other exclusion criteria may apply

• AST \> 17 U/L for women and AST \> 20 U/L for men. The AST inclusion criterion does not apply to participants with an eligible historical liver biopsy performed within 12 months of screening showing one of the following:
  • NAFLD Activity Score (NAS) ≥ 4 (with at least 1 point in each subcomponent of steatosis, inflammation, and ballooning) and NASH Clinical Research Network (CRN) fibrosis score of F0 OR
  • NAS ≥ 3 (with at least 1 point in each subcomponent of steatosis, inflammation, and ballooning) and NASH CRN fibrosis score of F1 OR
  • NAS ≥ 2 (with at least 1 point in subcomponent of ballooning or inflammation) and a NASH CRN fibrosis score of F2-3
• MRI-PDFF with ≥ 8% steatosis; this assessment must be performed within 4 weeks of the Baseline Visit.
• Presence of at least 1 of the following metabolic syndrome characteristics that increase the risk of MASH:
  • Diagnosis of type 2 diabetes managed with diet alone or diet and metformin (metformin dose must be stable for at least 1 month prior to screening) OR b. Presence of 3 or more components of metabolic syndrome: i. Fasting blood glucose ≥ 100 mg/dL (5.6 mmol/L) or treatment for elevated blood glucose with metformin ii. Systolic blood pressure ≥ 130 mm Hg, diastolic blood pressure ≥ 85 mm Hg, or treatment for hypertension iii. Serum TG ≥ 150 mg/dL (1.7 mmol/L) iv. Serum high-density lipoprotein cholesterol (HDL) \< 40 mg/dL (1 mmol/L) in men and \< 50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL v. Having overweight or obesity (body mass index \[BMI\] ≥ 25 kg/m2 \[BMI
  • 23 kg/m2 in Asians\]), or increased waist circumference ≥ 102 cm (40 in) in men and ≥ 88 cm (35 in) in women (men ≥ 90 cm \[35.4 in\]; women ≥ 80 cm \[31.5 in\] in Asians).
  • Other inclusion criteria may apply